Foghorn Therapeutics Stock In The News

FHTX Stock  USD 4.43  0.05  1.12%   
Our overall analysis of Foghorn Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Foghorn Therapeutics. The specific impact of Foghorn Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Foghorn Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Foghorn Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Foghorn Therapeutics Backtesting and Foghorn Therapeutics Hype Analysis.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Foghorn Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
https://www.globenewswire.com/news-release/2025/03/06/3038601/0/en/Foghorn-Therapeutics-Provides-Financial-Update-for-2024-and-2025-Strategic-Outlook.html
 Neutral
Macroaxis News: globenewswire.com
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
https://www.globenewswire.com/news-release/2025/02/25/3031828/0/en/Foghorn-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences.html
 Bullish
Yahoo News
Flagship Pioneering Announces Appointmen...
https://finance.yahoo.com/news/flagship-pioneering-announces-appointment-junaid-120000935.html
 Bullish
Yahoo News
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
https://finance.yahoo.com/news/invaio-sciences-appoints-andr-andonian-120000404.html
 Bullish
Yahoo News
With 39% stake, Foghorn Therapeutics Inc. (NASDAQ:FHTX) seems to have captured institutional investors' interest
https://finance.yahoo.com/news/39-stake-foghorn-therapeutics-inc-103414311.html
 Bullish
Yahoo News
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
https://finance.yahoo.com/news/foghorn-therapeutics-highlights-clinical-program-120000204.html
 Neutral
Yahoo News
Foghorn Therapeutics Announces CFO Departure
https://finance.yahoo.com/news/foghorn-therapeutics-announces-cfo-departure-210500623.html
 Bullish
Yahoo News
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why
https://finance.yahoo.com/news/foghorn-therapeutics-inc-fhtx-upgraded-170006481.html
 Bullish
Yahoo News
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%
https://finance.yahoo.com/news/much-upside-left-foghorn-therapeutics-145510274.html
 Bullish
Yahoo News
Foghorn Therapeutics Announces Clinical ...
https://finance.yahoo.com/news/foghorn-therapeutics-announces-clinical-data-120000679.html
 Neutral

Foghorn Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Foghorn and other traded companies coverage with news coverage. We help investors stay connected with Foghorn headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Foghorn Stock performance. Please note that trading solely based on the Foghorn Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Foghorn Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Foghorn Therapeutics investors visualize upcoming and past events in order to time the market based on Foghorn Therapeutics noise-free hype analysis.
Foghorn Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Foghorn earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Foghorn Therapeutics that are available to investors today. That information is available publicly through Foghorn media outlets and privately through word of mouth or via Foghorn internal channels. However, regardless of the origin, that massive amount of Foghorn data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Foghorn Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Foghorn Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Foghorn Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Foghorn Therapeutics alpha.

Foghorn Largest EPS Surprises

Earnings surprises can significantly impact Foghorn Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-03-09
2022-12-31-0.62-0.69-0.0711 
2022-08-09
2022-06-30-0.59-0.66-0.0711 
2024-10-31
2024-09-30-0.44-0.310.1329 
2022-05-09
2022-03-31-0.52-0.65-0.1325 
2024-03-07
2023-12-31-0.76-0.570.1925 
2024-08-08
2024-06-30-0.65-0.450.230 
View All Earnings Estimates

Foghorn Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Foghorn Therapeutics Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Yahoo News
10th of March 2025
Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science
at finance.yahoo.com 
Gurufocus Stories at Macroaxis
6th of March 2025
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
at gurufocus.com 
Yahoo News
28th of February 2025
Acquisition by Carlos Costa of 857 shares of Foghorn Therapeutics at 3.72 subject to Rule ...
at finance.yahoo.com 
Gurufocus Stories at Macroaxis
25th of February 2025
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
at gurufocus.com 
Google News at Macroaxis
14th of February 2025
FHTX Stock Price and Chart NASDAQFHTX - TradingView
at news.google.com 
Google News at Macroaxis
4th of February 2025
Foghorn Therapeutics Stock Rating Upgraded by B. Riley - MarketBeat
at news.google.com 
news
31st of January 2025
Foghorn Therapeutics Coverage Initiated by Analysts at B. Riley
at thelincolnianonline.com 
Google News at Macroaxis
29th of January 2025
B.Riley sets Foghorn stock Buy rating, 10 target - Investing.com
at news.google.com 
Google News at Macroaxis
24th of January 2025
Foghorn Therapeutics Stock Price, News Analysis - MarketBeat
at news.google.com 
Gurufocus Stories at Macroaxis
16th of December 2024
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic...
at gurufocus.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Foghorn Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Foghorn Therapeutics' short interest history, or implied volatility extrapolated from Foghorn Therapeutics options trading.

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.